Catégorie : Tout le CNR-MyRMA

Catégories
Documents Tout le CNR-MyRMA

Publications – Lèpre

Hasker, E., Assoumani, Y., Randrianantoandro, A., Ramboarina, S., Braet, S. M., Cauchoix, B., Baco, A., Mzembaba, A., Salim, Z., Amidy, M., Grillone, S., Attoumani, N., Grillone, S. H., Ronse, M., Peeters Grietens, K., Rakoto-Andrianarivelo, M., Harinjatovo, H., Supply, P., Snijders, R., Hoof, C., Tsoumanis, A., Suffys, P., Rasamoelina, T., Corstjens, P., Ortuno-Gutierrez, N., Geluk, A., Cambau, E. and De Jong, B. C. (2024). Post-exposure prophylaxis in leprosy (PEOPLE): a cluster randomised trial. The Lancet Global Health 12, e1017–e1026, http://doi.org/10.1016/S2214-109X(24)00062-7.
Mengeot, L., Jachiet, M., Bourrat, E., Mahé, A., Cambau, E., Bernard, E., Pasqualini, C., Chamouine, A., Truong, J., Dumaine, C., Bertolotti, A. and Franco, J. (2024). Effective management of severe chronic erythema nodosum leprosum in adolescent patient using ustekinumab and apremilast: A case report. Acad Dermatol Venereol 38, http://doi.org/10.1111/jdv.19552.
Chauffour, A., Lounis, N., Andries, K., Jarlier, V., Veziris, N. and Aubry, A. (2023). Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy Ed. Converse, P. J. PLoS Negl Trop Dis 17, e0011379, http://doi.org/10.1371/journal.pntd.0011379.
Jaume, L., Hau, E., Monsel, G., Mahé, A., Bertolotti, A., Petit, A., Le, B., Chauveau, M., Duhamel, E., Maisonobe, T., Bagot, M., Bouaziz, J.-D., Mougari, F., Cambau, E., Jachiet, M. and Groupe d’infectiologie en dermatologie et des infections sexuellement transmissibles (GrIDIST) (2023). Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study Ed. Poonawala, H. PLoS Negl Trop Dis 17, e0011238, http://doi.org/10.1371/journal.pntd.0011238.
Kirga, K. A., Nadlaou, B., Mahamat, A., Cambau, E., Penlap, V. and Godreuil, S. (2023). Genotypic characterization of Mycobacterium leprae strains resistant to rifampicin and ofloxacin in three health districts in Chad. J Drug Delivery Ther 13, 7–11, http://doi.org/10.22270/jddt.v13i3.5748.
Cambau, E. (2023). La lèpre aujourd’hui : de gros progrès mais des résistances. Bulletin de l’Académie Nationale de Médecine 207, 1053–1063, http://doi.org/10.1016/j.banm.2023.04.017.
Jouet, A., Braet, S. M., Gaudin, C., Bisch, G., Vasconcellos, S., Epaminondas Nicacio De Oliveira Do Livramento, R. E., Prado Palacios, Y. Y., Fontes, A. B., Lucena, N., Rosa, P., Moraes, M., La, K., Badalato, N., Lenoir, E., Ferré, A., Clément, M., Hasker, E., Grillone, S. H., Abdou, W., Said, A., Assoumani, Y., Attoumani, N., Laurent, Y., Cambau, E., De Jong, B. C., Suffys, P. N. and Supply, P. (2023). Hi-plex deep amplicon sequencing for identification, high-resolution genotyping and multidrug resistance prediction of Mycobacterium leprae directly from patient biopsies by using Deeplex Myc-Lep. eBioMedicine 93, 104649, http://doi.org/10.1016/j.ebiom.2023.104649.
Marijke Braet, S., Jouet, A., Aubry, A., Van Dyck-Lippens, M., Lenoir, E., Assoumani, Y., Baco, A., Mzembaba, A., Cambau, E., Vasconcellos, S. E. G., Rigouts, L., Suffys, P. N., Hasker, E., Supply, P. and de Jong, B. C. (2022). Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. The Lancet Microbe 3, e693–e700, http://doi.org/10.1016/S2666-5247(22)00117-3.
Aubry, A., Sammarco Rosa, P., Chauffour, A., Fletcher, M. L., Cambau, E. and Avanzi, C. (2022). Drug resistance in leprosy: An update following 70years of chemotherapy. Infectious Diseases Now 52, 243–251, http://doi.org/10.1016/j.idnow.2022.04.001.
Chauffour, A., Morel, F., Reibel, F., Petrella, S., Mayer, C., Cambau, E. and Aubry, A. (2021). A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance. Clinical Microbiology and Infection 27, 1601–1612, http://doi.org/10.1016/j.cmi.2021.07.007.
Ortuño-Gutiérrez, N., Mzembaba, A., Ramboarina, S., Andriamira, R., Baco, A., Braet, S., Younoussa, A., Cauchoix, B., Salim, Z., Amidy, M., Grillone, S., Rasamoelina, T., Cambau, E., Geluk, A., de Jong, B. C., Richardus, J. H. and Hasker, E. (2021). Exploring clustering of leprosy in the Comoros and Madagascar: A geospatial analysis. International Journal of Infectious Diseases 108, 96–101, http://doi.org/10.1016/j.ijid.2021.05.014.
Rousset, L., Sokal, A., Vignon-Pennamen, M.-D., Pagis, V., Rybojad, M., Lecorche, E., Mougari, F., Bagot, M., Bouaziz, J.-D. and Jachiet, M. (2020). Association d’une lèpre borderline tuberculoïde et d’une tuberculose : un cas et revue de la littérature. Annales de Dermatologie et de Vénéréologie 147, 886–891, http://doi.org/10.1016/j.annder.2020.09.571.
Avanzi, C., Lécorché, E., Rakotomalala, F. A., Benjak, A., Rapelanoro Rabenja, F., Ramarozatovo, L. S., Cauchoix, B., Rakoto-Andrianarivelo, M., Tió-Coma, M., Leal-Calvo, T., Busso, P., Boy-Röttger, S., Chauffour, A., Rasamoelina, T., Andrianarison, A., Sendrasoa, F., Spencer, J. S., Singh, P., Dashatwar, D. R., Narang, R., Berland, J.-L., Jarlier, V., Salgado, C. G., Moraes, M. O., Geluk, A., Randrianantoandro, A., Cambau, E. and Cole, S. T. (2020). Population Genomics of Mycobacterium leprae Reveals a New Genotype in Madagascar and the Comoros. Frontiers in Microbiology 11, URL: https://www.frontiersin.org/article/10.3389/fmicb.2020.00711 [Accessed March 2022].
Baron, V., Forfait, C., Colot, J., Carzola, C., Descloux, E., Cauchoix, B., Cambau, E., Gaumery, J., Grangeon, J. and Klement, E. (2019). Épidémiologie de la lèpre en Nouvelle-Calédonie de 1983 à 2017. BEH 400–405, URL: https://www.santepubliquefrance.fr/import/epidemiologie-de-la-lepre-en-nouvelle-caledonie-de-1983-a-2017 [Accessed February 2022].
Cambau, E., Saunderson, P., Matsuoka, M., Cole, S. T., Kai, M., Suffys, P., Rosa, P. S., Williams, D., Gupta, U. D., Lavania, M., Cardona-Castro, N., Miyamoto, Y., Hagge, D., Srikantam, A., Hongseng, W., Indropo, A., Vissa, V., Johnson, R. C., Cauchoix, B., Pannikar, V. K., Cooreman, E. a. W. D., Pemmaraju, V. R. R., Gillini, L., Kriswamati, A., Al-Samie, A. R., Issoufou, A., Tiendrebeogo, A., Kingalu, A., Randrianantoandro, A., Kumar, A., Chauffour, A., Win, A. A., Pandey, B., Agrawal, C. M., Widaningrum, C., Schmotzer, C., Kafando, C., Bhandari, C. M., Sema, C., Vidanagama, D. S., Scollard, D. M., Beyene, D., Morelo, E. F., Kassa, E. D., Ramarolahy, E. B., Claco, E., Villalon, E. E., Sidibe, F., Sakho, F., Abdoulaye, F., Guilengue, F. F., Gajete, F., Babu, G. R., Moussa, G., Thakur, G. D., Cabanos, G., Sock, G., Clugston, G., Zaidy, H., Watanabe, H., Kawuma, H. J., Mallari, I. B., Goulart, I. M. B., Ahamed, I., Subbanna, J., Houzeo, J. G., Luengu, J. N. M., Bertolli, J., Lloyd-Owen, J., Matheu, J., Brunelli, J. P., Alzate, J. C. B., Neupane, Kapil Dev, Osuga, K., Yamaguchi, K., Azam, K., Lin, K. M., Momoudu, K., Kyaw, K., Bide, L., Doanh, L. H., My, L. H., Shah, M., Kodio, M., Sidibe, M., Ebenezer, M., Grossi, M. A. de F., Balagon, M. F., Canlonon, M., Makino, M., Htoo, M. M., Ahmed, M. J., Nadine, M.-M., Roferos, F. O., Krismawati, H., Thida, M., Htoon, M. T., Neupane, K. D., Phuc, N. H. N., Van, N. H., Hai, N. P. N., Ishii, N., Soe, O., Amiel, O., Tossou, O., Konare, O., Joshi, P. L., Rao, P. V. R., Krishnamurthy, P., Brennan, P. J., Busso, P., Bhatia, R., Andrianarivelo, M. R., Ramdas, D. R., Chabi, R., Gusmao, R., DjupuriIzwardy, R., Soares, R. C. F. R., Jhadav, R., Buhrer, S., Cho, S.-N. R., Jianping, S., Lzumi, S., Barua, S., Chaitanya, S., Tiendrebeogo, S. M. R., Khang, T. H., Gillis, T. P., Mori, T., Vijayalakshmi, V., Kamara, V. D., Wei, W., Smith, W. C. S., Li, W., Lew, W., Al-Qubati, Y., Suzuki, Y. and Nanba, Y. (2018). Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clinical Microbiology and Infection 24, 1305–1310, http://doi.org/10.1016/j.cmi.2018.02.022.
Chauffour, A., Lecorche, E., Reibel, F., Mougari, F., Raskine, L., Aubry, A., Jarlier, V. and Cambau, E. (2018). Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015. Clinical Microbiology and Infection 24, 1213.e5-1213.e8, http://doi.org/10.1016/j.cmi.2018.06.004.
Mieras, L. F., Taal, A. T., van Brakel, W. H., Cambau, E., Saunderson, P. R., Smith, W. C. S., Prakoeswa, C. R. S., Astari, L., Scollard, D. M., do Nascimento, D. C., Grosset, J., Kar, H. K., Izumi, S., Gillini, L., Virmond, M. C. L. and Sturkenboom, M. G. G. (2018). An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++. BMC Infectious Diseases 18, 506, http://doi.org/10.1186/s12879-018-3402-4.
Cambau, E. (2018). Antileprosy drugs: mode of action and mechanisms. In: International textbook of leprosy, URL: https://internationaltextbookofleprosy.org/chapter/anti-leprosy-drugs-modes-action-and-mechanisms-resistance-mycobacterium-leprae [Accessed May 2022].
Machado, D., Lecorche, E., Mougari, F., Cambau, E. and Viveiros, M. (2018). Insights on Mycobacterium leprae Efflux Pumps and Their Implications in Drug Resistance and Virulence. Front Microbiol 9, http://doi.org/10.3389/fmicb.2018.03072.
Andre, E., Goeminne, L., Cabibbe, A., Beckert, P., Mukadi, B. K., Mathys, V., Gagneux, S., Niemann, S., Ingen, J. V. and Cambau, E. (2017). Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clinical Microbiology and Infection 23, 167–172, http://doi.org/10.1016/j.cmi.2016.09.006.
Raharolahy, O., Ramarozatovo, L. S., Ranaivo, I. M., Sendrasoa, F. A., Andrianarison, M., Andrianarivelo, M. R., Cambau, E. and Rabenja, F. R. (2016). A Case of Fluoroquinolone-Resistant Leprosy Discovered after 9 Years of Misdiagnosis. Case Reports in Infectious Diseases 2016, 4632369, http://doi.org/10.1155/2016/4632369.
Mieras, L., Anthony, R., van Brakel, W., Bratschi, M. W., van den Broek, J., Cambau, E., Cavaliero, A., Kasang, C., Perera, G., Reichman, L., Richardus, J. H., Saunderson, P., Steinmann, P. and Yew, W. W. (2016). Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy. Infectious Diseases of Poverty 5, 46, http://doi.org/10.1186/s40249-016-0140-y.
Reibel, F., Chauffour, A., Brossier, F., Jarlier, V., Cambau, E. and Aubry, A. (2015). New Insights into the Geographic Distribution of Mycobacterium leprae SNP Genotypes Determined for Isolates from Leprosy Cases Diagnosed in Metropolitan France and French Territories Ed. Johnson, C. PLOS Neglected Tropical Diseases 9, e0004141, http://doi.org/10.1371/journal.pntd.0004141.
Reibel, F., Cambau, E. and Aubry, A. (2015). Update on the epidemiology, diagnosis, and treatment of leprosy. Médecine et Maladies Infectieuses 45, 383–393, http://doi.org/10.1016/j.medmal.2015.09.002.
Reibel, F., Cambau, E. and Aubry, A. (2015). Histoire et actualité du traitement de la lèpre. Journal des Anti-Infectieux 17, 91–98, http://doi.org/10.1016/j.antinf.2015.01.004.
Veziris, N., Chauffour, A., Escolano, S., Henquet, S., Matsuoka, M., Jarlier, V. and Aubry, A. (2013). Resistance of M. leprae to Quinolones: A Question of Relativity? PLoS Negl Trop Dis 7, e2559, http://doi.org/10.1371/journal.pntd.0002559.
Gomez, C., Ponien, P., Serradji, N., Lamouri, A., Pantel, A., Capton, E., Jarlier, V., Anquetin, G. and Aubry, A. (2013). Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry 21, 948–956, http://doi.org/10.1016/j.bmc.2012.12.011.
Cambau, E., Chauffour-Nevejans, A., Tejmar-Kolar, L., Matsuoka, M. and Jarlier, V. (2012). Detection of Antibiotic Resistance in Leprosy Using GenoType LepraeDR, a Novel Ready-To-Use Molecular Test. PLoS Negl Trop Dis 6, e1739, http://doi.org/10.1371/journal.pntd.0001739.
Matrat, S., Cambau, E., Jarlier, V. and Aubry, A. (2008). Are All the DNA Gyrase Mutations Found in Mycobacterium leprae Clinical Strains Involved in Resistance to Fluoroquinolones? Antimicrob Agents Chemother 52, 745–747, http://doi.org/10.1128/AAC.01095-07.
Honoré, N., Roche, P. W., Grosset, J. H. and Cole, S. T. (2001). A method for rapid detection of rifampicin-resistant isolates of Mycobacterium leprae. Lepr Rev 72, 441–448, http://doi.org/10.5935/0305-7518.20010052.
Grosset, J. H. and Cole, S. T. (2001). Genomics and the chemotherapy of leprosy. Lepr Rev 72, 429–440, http://doi.org/10.5935/0305-7518.20010051.
Grosset, J. H. (2001). Newer drugs in leprosy. Int J Lepr Other Mycobact Dis 69, S14-18.
Nguyen, L. N., Cartel, J. L. and Grosset, J. H. (2000). Chemoprophylaxis of leprosy in the southern Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 years. Lepr Rev 71 Suppl, S33-35; discussion S35-36, http://doi.org/10.5935/0305-7518.20000064.
Ji, B. and Grosset, J. (2000). Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev 71 Suppl, S81-87, http://doi.org/10.5935/0305-7518.20000074.
Consigny, S., Bentoucha, A., Bonnafous, P., Grosset, J. and Ji, B. (2000). Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother 44, 2919–2921, http://doi.org/10.1128/AAC.44.10.2919-2921.2000.
Ji, B. and Grosset, J. H. (1999). Drugs and regimens for preventive therapy against tuberculosis, disseminated Mycobacterium avium complex infection and leprosy. Int J Lepr Other Mycobact Dis 67, S45-55.
Ji, B., Sow, S., Perani, E., Lienhardt, C., Diderot, V. and Grosset, J. (1998). Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother 42, 1115–1120, http://doi.org/10.1128/AAC.42.5.1115.
Ji, B., Jamet, P., Sow, S., Perani, E. G., Traore, I. and Grosset, J. H. (1997). High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Antimicrob Agents Chemother 41, 1953–1956, http://doi.org/10.1128/AAC.41.9.1953.
Mane, I., Cartel, J. L. and Grosset, J. H. (1997). Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. Int J Lepr Other Mycobact Dis 65, 224–229.
Grosset, J. (1997). Whither short-course chemotherapy for leprosy? Indian J Lepr 69, 119–120.
Ji, B., Levy, L. and Grosset, J. H. (1996). Chemotherapy of leprosy: progress since the Orlando Congress, and prospects for the future. Int J Lepr Other Mycobact Dis 64, S80-88; discussion S88-90.
Ji, B., Jamet, P., Perani, E. G., Sow, S., Lienhardt, C., Petinon, C. and Grosset, J. H. (1996). Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother 40, 2137–2141, http://doi.org/10.1128/AAC.40.9.2137.
Ji, B., Perani, E. G., Petinom, C. and Grosset, J. H. (1996). Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother 40, 393–399, http://doi.org/10.1128/AAC.40.2.393.
Ji, B., Perani, E. G., Petinom, C., N’Deli, L. and Grosset, J. H. (1994). Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents Chemother 38, 662–667, http://doi.org/10.1128/AAC.38.4.662.
Xiong, J. H., Ji, B., Perani, E. G., Pétinon, C. and Grosset, J. H. (1994). Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice. Int J Lepr Other Mycobact Dis 62, 37–42.
Honoré, N., Perrani, E., Telenti, A., Grosset, J. and Cole, S. T. (1993). A simple and rapid technique for the detection of rifampin resistance in Mycobacterium leprae. Int J Lepr Other Mycobact Dis 61, 600–604.
Ji, B., Jamet, P., Perani, E. G., Bobin, P. and Grosset, J. H. (1993). Powerful Bactericidal Activities of Clarithromycin and Minocycline against Mycobacterium leprae in Lepromatous Leprosy. J Infect Dis 168, 188–190, http://doi.org/10.1093/infdis/168.1.188.
Ji, B., Perani, E. G., Petinon, C. and Grosset, J. H. (1992). Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. Int J Lepr Other Mycobact Dis 60, 556–561.
Ji, B., Perani, E. G. and Grosset, J. H. (1991). Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 35, 579–581, http://doi.org/10.1128/AAC.35.3.579.
Ji, B. and Grosset, J. (1991). Ofloxacin for the treatment of leprosy. Acta Leprol 7, 321–326.
Catégories
Documents Tout le CNR-MyRMA

Publications – Buruli

Phillips, R. O., Robert, J., Abass, K. M., Thompson, W., Sarfo, F. S., Wilson, T., Sarpong, G., Gateau, T., Chauty, A., Omollo, R., Ochieng Otieno, M., Egondi, T. W., Ampadu, E. O., Agossadou, D., Marion, E., Ganlonon, L., Wansbrough-Jones, M., Grosset, J., Macdonald, J. M., Treadwell, T., Saunderson, P., Paintsil, A., Lehman, L., Frimpong, M., Sarpong, N. F., Saizonou, R., Tiendrebeogo, A., Ohene, S.-A., Stienstra, Y., Asiedu, K. B., van der Werf, T. S., Osei Mireku, S., Abotsi, J., Adu Poku, J. K., Asamoah-Frimpong, R., Osei-Wusu, B., Sarpong, E., Konadu, B., Opoku, E., Forson, M., Ndogyele, M., Ofori, E., Aboagye, F., Berko, T., Amofa, G., Nsiah, A., Mensah-Bonsu, J., Ofori Nyarko, J., Amoako, Y. A., Koranteng Tannor, E., Boakye-Appiah, J., Dzibordzi Loglo, A., Sarpong-Duah, M., Agbavor, B., Ardent, M. F., Yamadjako, A., Adanmado Gersande, N., Adeye, A., Kindjinou, M., Akpolan, Kiki, M., Sodjinou, E., Guegnard, C., Klis, S.-A., Velding, K., Omansen, T., Ofori-Adjei, D., Eyangoh, S., Knell, A. and Faber, W. (2020). Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. The Lancet 395, 1259–1267, http://doi.org/10.1016/S0140-6736(20)30047-7.
Chauffour, A., Robert, J., Veziris, N., Aubry, A., Pethe, K. and Jarlier, V. (2020). Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLOS Neglected Tropical Diseases 14, e0007857, http://doi.org/10.1371/journal.pntd.0007857.
Scherr, N., Bieri, R., Thomas, S. S., Chauffour, A., Kalia, N. P., Schneide, P., Ruf, M.-T., Lamelas, A., Manimekalai, M. S. S., Grüber, G., Ishii, N., Suzuki, K., Tanner, M., Moraski, G. C., Miller, M. J., Witschel, M., Jarlier, V., Pluschke, G. and Pethe, K. (2018). Targeting the Mycobacterium ulcerans cytochrome bc 1 : aa 3 for the treatment of Buruli ulcer. Nature Communications 9, 5370, http://doi.org/10.1038/s41467-018-07804-8.
Chauffour, A., Robert, J., Veziris, N., Aubry, A. and Jarlier, V. (2016). Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium ulcerans Infection in Mice. PLOS Neglected Tropical Diseases 10, e0005066, http://doi.org/10.1371/journal.pntd.0005066.
Ruf, M.-T., Schütte, D., Chauffour, A., Jarlier, V., Ji, B. and Pluschke, G. (2012). Chemotherapy-Associated Changes of Histopathological Features of Mycobacterium ulcerans Lesions in a Buruli Ulcer Mouse Model. Antimicrob Agents Chemother 56, 687–696, http://doi.org/10.1128/AAC.05543-11.
Marsollier, L., Aubry, A., Carbonnelle, E., Canaan, S., Cambau, E. and Herrmann, J.-L. (2010). Les Mycobactérioses cutanées dues à Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium abscessus, Mycobacterium chelonae et autres mycobactéries non tuberculeuses, L’Encyclopédie Médico-chirurgicale.
Ji, B., Chauffour, A., Aubry, A., Robert, J., Ibrahim, M. and Jarlier, V. (2009). Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 53, 2955–2959, http://doi.org/10.1128/AAC.00011-09.
Ji, B., Chauffour, A., Robert, J. and Jarlier, V. (2008). Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 52, 1912–1916, http://doi.org/10.1128/AAC.00193-08.
Ji, B., Chauffour, A., Robert, J., Lefrançois, S. and Jarlier, V. (2007). Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 51, 3737–3739, http://doi.org/10.1128/AAC.00730-07.
Lefrançois, S., Robert, J., Chauffour, A., Ji, B. and Jarlier, V. (2007). Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin. Antimicrob Agents Chemother 51, 645–650, http://doi.org/10.1128/AAC.00821-06.
Ji, B., Lefrançois, S., Robert, J., Chauffour, A., Truffot, C. and Jarlier, V. (2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 50, 1921–1926, http://doi.org/10.1128/AAC.00052-06.
Dega, H., Bentoucha, A., Robert, J., Jarlier, V. and Grosset, J. (2002). Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 46, 3193–3196, http://doi.org/10.1128/AAC.46.10.3193-3196.2002.
Bentoucha, A., Robert, J., Dega, H., Lounis, N., Jarlier, V. and Grosset, J. (2001). Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 45, 3109–3112, http://doi.org/10.1128/AAC.45.11.3109-3112.2001.
Dega, H., Robert, J., Bonnafous, P., Jarlier, V. and Grosset, J. (2000). Activities of Several Antimicrobials againstMycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 44, 2367–2372, http://doi.org/10.1128/AAC.44.9.2367-2372.2000.
Catégories
Documents Tout le CNR-MyRMA

Publications – Tuberculose

Seules les publications les plus récentes sont présentées – Pour voir plus de publications aller à la page de recherche : toutes les publications
Only the most recent publications are displayed – to see more, go to the search page : all publications

Maitre, T., Godmer, A., Mory, C., Chauffour, A., Mai, T. C., El Helali, N., Aubry, A. and Veziris, N. (2024). Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis Ed. Wasserman, S. Antimicrob Agents Chemother e00583-24, http://doi.org/10.1128/aac.00583-24.
Godefroy, N., Monsel, G., Jauréguiberry, S., Henry, B., Véziris, N., Aubry, A., Robert, J., Jachym, M., Caumes, E. and Pourcher, V. (2024). Lessons learned from treating drug-resistant TB and how to apply these to drug-susceptible TB. int j tuberc lung dis 28, 357–359, http://doi.org/10.5588/ijtld.23.0548.
Rupasinghe, P., Ashraf, A., Barreda, N., Parveen, S., Zubair, M., Calderon, R., Asif, S., Hirani, N., Chingisova, L., Bulane, A., Hang, P. T., Ha, D. T., Ardizzoni, E., Kursheed, N., De Rijk, W. B., Rigouts, L., Guglielmetti, L., Mitnick, C. and De Jong, B. C. (2024). Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin Ed. Wasserman, S. Antimicrob Agents Chemother 68, e01701-23, http://doi.org/10.1128/aac.01701-23.
Veziris, N., Aubry, A., Bonnet, I., Petersen, T., Poignon, C., Gydé, E., Guglielmetti, L. and Robert, J. (2024). Actualités sur la tuberculose à bacilles multirésistants aux antibiotiques et ses nouveaux traitements. Bull Épid Hebdo 127–131, URL: http://beh.santepubliquefrance.fr/beh/2024/6-7/2024_6-7_4.html [Accessed March 2024].
Lange, C., Kherabi, Y., Guglielmetti, L., Duarte, R. and Günther, G. (2024). Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author’s response. Clinical Microbiology and Infection 30, 1207–1208, http://doi.org/10.1016/j.cmi.2024.06.009.
Friesen, I., Saluzzo, F., Groenheit, R., Aubry, A., Anthony, R., Niemann, S., Mathys, V., Cirillo, D. M., Indra, A., Mathys, V., Atanasova, Y., Obrovac, M., Žmak, L., Pieridou, D., Dvořákov, V., Troels Lillebæk, Kummik, T., Klaos, K., Soini, H., Haanperä-Heikkinen, M., Mentula, S., Jérôme, R., Cambau, E., Niemann, S., Panayotis, I., Papaventsis, D., Bakos, Á., Szél, V., Lőrinczi, L. K., Fitzgibbon, M., Boyle, B., Cirillo, D. M., Giannoni, F., Pole, I., Norvaiša, I., Vasiliauskaite, L., Perrin, M., Deguara, C., Anthony, R., Mengshoel, A. T., Augustynowicz-Kopeć, E., Macedo, R., Coriu, R. M., Porvaznik, I., Klemen, Š., Herrera-León, L., Groenheit, R. and Werngren, J. (2024). Re: “Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe” by Lange et al. Clinical Microbiology and Infection S1198743X24002775, http://doi.org/10.1016/j.cmi.2024.06.001.
Maitre, T., Baulard, A., Aubry, A. and Veziris, N. (2024). Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis. Infectious Diseases Now 54, 104807, http://doi.org/10.1016/j.idnow.2023.104807.
Maitre, T., Guglielmetti, L., Robert, J., Aubry, A. and Veziris, N. (2024). Avancées dans l’antibiothérapie de la tuberculose. Rev Prat 74, 239–244.
Campbell, J. R., Brode, S. K., Barry, P., Bastos, M. L., Bonnet, M., Guglielmetti, L., Kempker, R., Klimuk, D., Laborín, R. L., Milanov, V., Singla, R., Skrahina, A., Trajman, A., Van Der Werf, T. S., Viiklepp, P. and Menzies, D. (2023). Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis. Thorax thorax-2023-220249, http://doi.org/10.1136/thorax-2023-220249.
Du Cros, P., Greig, J., Alffenaar, J.-W. C., Cross, G. B., Cousins, C., Berry, C., Khan, U., Phillips, P. P. J., Velásquez, G. E., Furin, J., Spigelman, M., Denholm, J. T., Thi, S. S., Tiberi, S., Huang, G. K. L., Marks, G. B., Turkova, A., Guglielmetti, L., Chew, K. L., Nguyen, H. T., Ong, C. W. M., Brigden, G., Singh, K. P., Motta, I., Lange, C., Seddon, J. A., Nyang’wa, B.-T., Maug, A. K. J., Gler, M. T., Dooley, K. E., Quelapio, M., Tsogt, B., Menzies, D., Cox, V., Upton, C. M., Skrahina, A., McKenna, L., Horsburgh, C. R., Dheda, K. and Marais, B. J. (2023). Standards for clinical trials for treating TB. int j tuberc lung dis 27, 885–898, http://doi.org/10.5588/ijtld.23.0341.
Patil, S. B., Tamirat, M., Khazhidinov, K., Ardizzoni, E., Atger, M., Austin, A., Baudin, E., Bekhit, M., Bektasov, S., Berikova, E., Bonnet, M., Caboclo, R., Chaudhry, M., Chavan, V., Cloez, S., Coit, J., Coutisson, S., Dakenova, Z., De Jong, B. C., Delifer, C., Demaisons, S., Do, J. M., Dos Santos Tozzi, D., Ducher, V., Ferlazzo, G., Gouillou, M., Khan, U., Kunda, M., Lachenal, N., LaHood, A. N., Lecca, L., Mazmanian, M., McIlleron, H., Moreau, M., Moschioni, M., Nahid, P., Osso, E., Oyewusi, L., Panda, S., Pâquet, A., Thuong Huu, P., Pichon, L., Rich, M. L., Rupasinghe, P., Salahuddin, N., Sanchez Garavito, E., Seung, K. J., Velásquez, G. E., Vallet, M., Varaine, F., Yuya-Septoh, F. J., Mitnick, C. D. and Guglielmetti, L. (2023). Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial. Trials 24, 773, http://doi.org/10.1186/s13063-023-07701-6.
Sahal, M. R., Senelle, G., La, K., Panda, T. W., Taura, D. W., Guyeux, C., Cambau, E. and Sola, C. (2023). Mycobacterium tuberculosis complex drug-resistance, phylogenetics, and evolution in Nigeria: Comparison with Ghana and Cameroon Ed. Rayner, S. PLoS Negl Trop Dis 17, e0011619, http://doi.org/10.1371/journal.pntd.0011619.
Günther, G., Guglielmetti, L., Leu, C., van Leth, F. and Lange, C. (2023). Relative cost of multidrug-resistant TB medicines in Europe. The International Journal of Tuberculosis and Lung Disease 27, 341–344, http://doi.org/10.5588/ijtld.23.0026.
Campbell, J. R., Chan, E. D., Anderson, L. F., Bonnet, M., Brode, S. K., Cegielski, J. P., Guglielmetti, L., Singla, R., Fox, G. J., Skrahina, A., Rodrigues, D., Kuksa, L., Viiklepp, P. and Menzies, D. (2023). Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes. The International Journal of Tuberculosis and Lung Disease 27, 338–340, http://doi.org/10.5588/ijtld.22.0678.
Guthmann, J.-P., Fraisse, P., Bonnet, I. and Robert, J. (2023). Active tuberculosis screening among the displaced population fleeing Ukraine, France, February to October 2022. Eurosurveillance 28, http://doi.org/10.2807/1560-7917.ES.2023.28.12.2300155.
Aubry, A. and Veziris, N. (2023). La tuberculose, l’une des plus anciennes maladies infectieuses : quelles avancées récentes majeures ? Med Sci (Paris) 39, 203–204, http://doi.org/10.1051/medsci/2023054.
Masini, T., Furin, J., Udwadia, Z. and Guglielmetti, L. (2023). Optimal management of drug-resistant tuberculosis: Can India lead the way? Indian Journal of Medical Research 157, 220, http://doi.org/10.4103/ijmr.ijmr_300_23.
Domínguez, José, Boeree, M. J., Cambau, E., Chesov, D., Conradie, F., Cox, V., Dheda, K., Dudnyk, A., Farhat, M. R., Gagneux, S., Grobusch, M. P., Gröschel, M. I., Guglielmetti, L., Kontsevaya, I., Lange, B., van Leth, F., Lienhardt, C., Mandalakas, Anna M, Maurer, F. P., Merker, M., Miotto, P., Molina-Moya, B., Morel, F., Niemann, S., Veziris, N., Whitelaw, A., Horsburgh, Charles R, Lange, C., Domínguez, Jose, Boeree, M. J., Cambau, E., Chesov, D., Conradie, F., Cox, V., Dheda, K., Dudnyk, A., Farhat, M. R., Gagneux, S., Grobusch, M. P., Gröschel, M. I., Guglielmetti, L., Kontsevaya, I., Lange, B., van Leth, F., Lienhardt, C., Mandalakas, Anna Maria, Maurer, F., Merker, M., Miotto, P., Molina-Moya, B., Morel, F., Niemann, S., Veziris, N., Whitelaw, A., Horsburgh, Charles Robert and Lange, C. (2023). Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. The Lancet Infectious Diseases, http://doi.org/10.1016/S1473-3099(22)00875-1.
Barbier, E., Fouchet, T., Hartmann, A., Cambau, E., Mougari, F., Dubois, C., Lubetzki, M. and Rochelet, M. (2023). Rapid electrochemical detection of Mycobacterium tuberculosis in sputum by measuring Ag85 activity with disposable carbon sensors. Talanta 253, 123927, http://doi.org/10.1016/j.talanta.2022.123927.
Khan, U. and Guglielmetti, L. (2023). Tailored TPT for drug-resistant TB - promoting equity and access to optimal care. Int J Tuberc Lung Dis 27, 89b–890, http://doi.org/10.5588/ijtld.22.0538.
Günther, G., Guglielmetti, L., Leu, C., Lange, C., van Leth, F., Hasan Hafizi, Khachatryan, N., Aroyan, H., Kabasakalyan, E., Knappik, M., Skrahina, A., Klimuk, D., Nikolenka, A., Muylle, I., Milanov, V., Velkovska, D., Tarinska, N., Bachiyska, E., Jankovic, M., Pieridou, D., Adamide, T., Nicolaou, N., Vasakova, M., Sukholytka, M., Kopeckà, E., Folkvardsen, D. B., Svensson, E., Danilovits, M., Kummik, T., Vasankari, T., Fréchet-Jachym, M., Nahmiash, A., Togonidze, T., Avaliani, Z., Kinkladze, I., Aspindzelashvili, R., Bichashvili, T., Losaberidze, G., Merabishvili, T., Kalsdorf, B., Manika, K., Tsiakitzis, K., Bakos, A., Ægisdóttir, T. R., Michelsen, G. S., Karlsdóttir, K., McLaughlin, A.-M., Fitzgibbon, M., Chemtob, D., Codecasa, L. R., Ferrarese, M., Torri, S., Gjocaj, M., Kuksa, L., Davidaviciene, E., Wirtz, G., Perrin, M., Asciak, A. P., Chesov, D., de Lange, W., Akkerman, O., Poposka, B. I., Mack, U., Jensenius, M., Kvalvik, L., Mengshoel, A. T., Kruczak, K., Duarte, R., Ribeiro, N., Ibraim, E., Kaluzhenina, A., Barkanova, O., Pesut, D., Solovic, I., Svetina, P., Souza-Galvão, M.-L. de, Millet, J.-P., Casas, X., Vives, M., Bruchfeld, J., Dalemo, P., Jonsson, J., Aeschbacher, K., Keller, P., Özkara, S., Tiberi, S., Chen, C., Terleeva, Y. and Dudnyk, A. (2023). Availability and costs of medicines for the treatment of tuberculosis in Europe. Clinical Microbiology and Infection 29, 77–84, http://doi.org/10.1016/j.cmi.2022.07.026.
Senelle, G., Sahal, M. R., La, K., Billard-Pomares, T., Marin, J., Mougari, F., Bridier-Nahmias, A., Carbonnelle, E., Cambau, E., Refrégier, G., Guyeux, C. and Sola, C. (2023). Towards the reconstruction of a global TB history using a new pipeline “TB-Annotator". Tuberculosis 143, 102376, http://doi.org/10.1016/j.tube.2023.102376.
Motta, I., Boeree, M., Chesov, D., Dheda, K., Günther, G., Horsburgh, C. R., Kherabi, Y., Lange, C., Lienhardt, C., McIlleron, H. M., Paton, N. I., Stagg, H. R., Thwaites, G., Udwadia, Z., Van Crevel, R., Velásquez, G. E., Wilkinson, R. J., Guglielmetti, L., Motta, I., Kherabi, Y., Van Crevel, R. and Guglielmetti, L. (2023). Recent advances in the treatment of tuberculosis. Clinical Microbiology and Infection S1198743X23003397, http://doi.org/10.1016/j.cmi.2023.07.013.
Holmgaard, F. B., Guglielmetti, L., Lillebaek, T., Andersen, Å. B., Wejse, C. and Dahl, V. N. (2022). Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Clin Infect Dis ciac876, http://doi.org/10.1093/cid/ciac876.
Wetzstein, N., Drummer, A.-P., Bockey, A., Herrmann, E., Küpper-Tetzel, C. P., Graf, C., Koch, B., Goetsch, U., Vehreschild, M. J. G. T., Guglielmetti, L., Lange, B., Wichelhaus, T. A. and Stephan, C. (2022). Occurrence of extrapulmonary tuberculosis is associated with geographical origin: spatial characteristics of the Frankfurt TB cohort 2013–2018. Infection, http://doi.org/10.1007/s15010-022-01921-9.
Kherabi, Y., Tunesi, S., Kay, A. and Guglielmetti, L. (2022). Preventive Therapy for Contacts of Drug-Resistant Tuberculosis. Pathogens 11, 1189, http://doi.org/10.3390/pathogens11101189.
Khan, U. and Guglielmetti, L. (2022). Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB. The International Journal of Tuberculosis and Lung Disease 26, 900–901, http://doi.org/10.5588/ijtld.22.0328.
Kherabi, Y., Fréchet-Jachym, M., Rioux, C., Yazdanpanah, Y., Méchaï, F., Pourcher, V., Robert, J. and Guglielmetti, L. (2022). Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019. Emerg Infect Dis 28, 1796–1804, http://doi.org/10.3201/eid2809.220458.
De Castro, N., Mechaï, F., Bachelet, D., Canestri, A., Joly, V., Vandenhende, M., Boutoille, D., Kerjouan, M., Veziris, N., Molina, J. M., Grall, N., Tattevin, P., Laouénan, C., Yazdanpanah, Y. and for the FAST TB Study Group (2022). Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB). Open Forum Infectious Diseases 9, ofac353, http://doi.org/10.1093/ofid/ofac353.
Kraef, C., Lindquist, E., Svensson, E. and Cambau, E. (2022). Diagnostic toolkit for tuberculosis: should we include urine lipoarabinomannan (LAM) detection in the WHO European Region? Clinical Microbiology and Infection, http://doi.org/10.1016/j.cmi.2022.06.022.
Bachir, M., Guglielmetti, L., Tunesi, S., Billard-Pomares, T., Chiesi, S., Jaffré, J., Langris, H., Pourcher, V., Schramm, F., Lemaître, N. and Robert, J. (2022). Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. Journal of Infection 85, 24–30, http://doi.org/10.1016/j.jinf.2022.05.017.
Maitre, T., Morel, F., Brossier, F., Sougakoff, W., Jaffre, J., Cheng, S., Veziris, N., Aubry, A. and on behalf of the NRC-MyRMA (2022). How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance. Microorganisms 10, 1436, http://doi.org/10.3390/microorganisms10071436.
Eimer, J., Fréchet-Jachym, M., Le Dû, D., Caumes, E., El-Helali, N., Marigot-Outtandy, D., Mechai, F., Peytavin, G., Pourcher, V., Rioux, C., Yazdanpanah, Y., Robert, J., Guglielmetti, L. and for the LZDM group (2022). Increased linezolid plasma concentrations are associated with the development of severe toxicity in MDR-TB treatment. Clinical Infectious Diseases ciac485, http://doi.org/10.1093/cid/ciac485.
Bonnet, I., Haddad, E., Guglielmetti, L., Bémer, P., Bernard, L., Bourgoin, A., Brault, R., Catho, G., Caumes, E., Escaut, L., Fourniols, E., Fréchet-Jachym, M., Gaudart, A., Guillot, H., Lafon-Desmurs, B., Lanoix, J.-P., Lanotte, P., Lemaignen, A., Lemaire, B., Lemaitre, N., Michau, C., Morand, P., Mougari, F., Marigot-Outtandy, D., Patrat-Delon, S., Perpoint, T., Piau, C., Pourcher, V., Zarrouk, V., Zeller, V., Veziris, N., Jauréguiberry, S. and Aubry, A. (2022). Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Microorganisms 10, 1215, http://doi.org/10.3390/microorganisms10061215.
Guglielmetti, L., Günther, G., Leu, C., Cirillo, D., Duarte, R., Garcia-Basteiro, A. L., Goletti, D., Jankovic, M., Kuksa, L., Maurer, F. P., Méchaï, F., Tiberi, S., Leth, F. van, Veziris, N. and Lange, C. (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00388-2022.
Le Ray, L. F., Aubry, A., Sougakoff, W., Revest, M., Robert, J., Bonnet, I., Veziris, N. and Morel, F. (2022). atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure. Emerg Infect Dis 28, 1062–1064, http://doi.org/10.3201/eid2805.212517.
Group, A. S. T., Georghiou, S. B., Rodwell, T. C., Korobitsyn, A., Abbadi, S. H., Ajbani, K., Alffenaar, J.-W., Alland, D., Alvarez, N., Andres, S., Ardizzoni, E., Aubry, A., Baldan, R., Ballif, M., Barilar, I., Böttger, E. C., Chakravorty, S., Claxton, P. M., Cirillo, D. M., Comas, I., Coulter, C., Denkinger, C. M., Derendinger, B., Desmond, E. P., Steenwinkel, J. E. M. de, Dheda, K., Diacon, A. H., Dolinger, D. L., Dooley, K. E., Egger, M., Ehsani, S., Farhat, M. R., Fattorini, L., Finci, I., Ray, L. F. L., Furió, V., Groenheit, R., Gumbo, T., Heysell, S. K., Hillemann, D., Hoffmann, H., Hsueh, P.-R., Hu, Y., Huang, H., Hussain, A., Ismail, F., Izumi, K., Jagielski, T., Johnson, J. L., Kambli, P., Kaniga, K., Karunaratne, G. H. R. E., Sharma, M. K., Keller, P. M., Kelly, E. C., Kholina, M., Kohli, M., Kranzer, K., Laurenson, I. F., Limberis, J., Lin, S.-Y. G., Liu, Y., López-Gavín, A., Lyander, A., Machado, D., Martinez, E., Masood, F., Mitarai, S., Mvelase, N. R., Niemann, S., Nikolayevskyy, V., Maurer, F. P., Merker, M., Miotto, P., Omar, S. V., Otto-Knapp, R., Palaci, M., Gutiérrez, J. J. P., Peacock, S. J., Peloquin, C. A., Perera, J., Pierre-Audigier, C., Pholwat, S., Posey, J. E., Prammananan, T., Rigouts, L., Robledo, J., Rockwood, N., Rodrigues, C., Salfinger, M., Schechter, M. C., Seifert, M., Sengstake, S., Shinnick, T., Shubladze, N., Sintchenko, V., Sirgel, F., Somasundaram, S., Sterling, T. R., Spitaleri, A., Streicher, E., Supply, P., Svensson, E., Tagliani, E., Tahseen, S., Takaki, A., Theron, G., Torrea, G., Deun, A. V., Ingen, J. van, Rie, A. V., Soolingen, D. van, Jr, R. V., Venter, A., Veziris, N., Villellas, C., Viveiros, M., Warren, R., Wen, S., Werngren, J., Wilkinson, R. J., Yang, C., Yılmaz, F. F., Zhang, T., Zimenkov, D., Ismail, N., Köser, C. U. and Schön, T. (2022). Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00166-2022.
Tunesi, S., Dû, D. L., Gualano, G., Millet, J.-P., Skrahin, A., Bothamley, G., Casas, X., Goletti, D., Lange, C., Musso, M., Palmieri, F., Pourcher, V., Rioux, C., Skrahina, A., Veziris, N., Viatushka, D., Jachym-Fréchet, M. and Guglielmetti, L. (2022). Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. Journal of Infection, http://doi.org/10.1016/j.jinf.2022.03.004.
Migliori, G. B., Wu, S. J., Matteelli, A., Zenner, D., Goletti, D., Ahmedov, S., Al-Abri, S., Allen, D. M., Balcells, M. E., Garcia-Basteiro, A. L., Cambau, E., Chaisson, R. E., Chee, C. B. E., Dalcolmo, M. P., Denholm, J. T., Erkens, C., Esposito, S., Farnia, P., Friedland, J. S., Graham, S., Hamada, Y., Harries, A. D., Kay, A. W., Kritski, A., Manga, S., Marais, B. J., Menzies, D., Ng, D., Petrone, L., Rendon, A., Silva, D. R., Schaaf, H. S., Skrahina, A., Sotgiu, G., Thwaites, G., Tiberi, S., Tukvadze, N., Zellweger, J.-P., D’Ambrosio, L., Centis, R. and Ong, C. W. M. (2022). Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis 26, 190–205, http://doi.org/10.5588/ijtld.21.0753.
Guyeux, C., Senelle, G., Refrégier, G., Bretelle-Establet, F., Cambau, E. and Sola, C. (2022). Connection between two historical tuberculosis outbreak sites in Japan, Honshu, by a new ancestral Mycobacterium tuberculosis L2 sublineage. Epidemiology & Infection 150, http://doi.org/10.1017/S0950268822000048.
Nyang’wa, B. T., LaHood, A. N., Mitnick, C. D. and Guglielmetti, L. (2021). TB research requires strong protections, innovation, and increased funding in response to COVID-19. Trials 22, 1–3, http://doi.org/10.1186/s13063-021-05331-4.
Bonnet, I., Enouf, V., Morel, F., Ok, V., Jaffré, J., Jarlier, V., Aubry, A., Robert, J. and Sougakoff, W. (2021). A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples. Front Cell Infect Microbiol 11, 707244, http://doi.org/10.3389/fcimb.2021.707244.
Guglielmetti, L., Ardizzoni, E., Atger, M., Baudin, E., Berikova, E., Bonnet, M., Chang, E., Cloez, S., Coit, J. M., Cox, V., de Jong, B. C., Delifer, C., Do, J. M., Tozzi, D. D. S., Ducher, V., Ferlazzo, G., Gouillou, M., Khan, A., Khan, U., Lachenal, N., LaHood, A. N., Lecca, L., Mazmanian, M., McIlleron, H., Moschioni, M., O’Brien, K., Okunbor, O., Oyewusi, L., Panda, S., Patil, S. B., Phillips, P. P. J., Pichon, L., Rupasinghe, P., Rich, M. L., Saluhuddin, N., Seung, K. J., Tamirat, M., Trippa, L., Cellamare, M., Velásquez, G. E., Wasserman, S., Zimetbaum, P. J., Varaine, F. and Mitnick, C. D. (2021). Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials 22, 651, http://doi.org/10.1186/s13063-021-05491-3.
Roelens, M., Battista Migliori, G., Rozanova, L., Estill, J., Campbell, J. R., Cegielski, J. P., Tiberi, S., Palmero, D., Fox, G. J., Guglielmetti, L., Sotgiu, G., Brust, J. C. M., Bang, D., Lienhardt, C., Lange, C., Menzies, D., Keiser, O. and Raviglione, M. (2021). Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med 204, 713–722, http://doi.org/10.1164/rccm.202009-3527OC.
Veziris, N., Bonnet, I., Morel, F., Guglielmetti, L., Maitre, T., Ray, L. F. L., Sougakoff, W., Robert, J. and Aubry, A. (2021). Impact of the revised definition of extensively drug-resistant tuberculosis. European Respiratory Journal 58, http://doi.org/10.1183/13993003.00641-2021.
Starshinova, A., Guglielmetti, L., Rzhepishevska, O., Ekaterincheva, O., Zinchenko, Yu. and Kudlay, D. (2021). Diagnostics and management of tuberculosis and COVID-19 in a patient with pneumothorax (clinical case). J Clin Tuberc Other Mycobact Dis 24, 100259, http://doi.org/10.1016/j.jctube.2021.100259.
Ok, V., Aubry, A., Morel, F., Bonnet, I., Robert, J. and Sougakoff, W. (2021). Rapid Molecular Diagnosis of Tuberculosis and Its Resistance to Rifampicin and Isoniazid with Automated MDR/MTB ELITe MGB® Assay. Antibiotics 10, 797, http://doi.org/10.3390/antibiotics10070797.
Hewison, C. and Guglielmetti, L. (2021). Cardiac safety of multidrug-resistant tuberculosis treatment: moving towards individualised monitoring. Lancet Infect Dis 21, 894–895, http://doi.org/10.1016/S1473-3099(20)30836-7.
Guglielmetti, L. and Varaine, F. (2021). The coming-of-age of bedaquiline: a tale with an open ending. European Respiratory Journal 57, http://doi.org/10.1183/13993003.00066-2021.
World Health Organisation (2021). Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine), WHO, Geneva, URL: https://www.who.int/publications/i/item/technical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-(rifampicin-rifabutin-and-rifapentine) [Accessed March 2022].

Catégories
Documents Tout le CNR-MyRMA

Publications du CNR en 2022

Aubry, A., Sammarco Rosa, P., Chauffour, A., Fletcher, M. L., Cambau, E. and Avanzi, C. (2022). Drug resistance in leprosy: An update following 70years of chemotherapy. Infectious Diseases Now 52, 243–251, http://doi.org/10.1016/j.idnow.2022.04.001.
Bachir, M., Guglielmetti, L., Tunesi, S., Billard-Pomares, T., Chiesi, S., Jaffré, J., Langris, H., Pourcher, V., Schramm, F., Lemaître, N. and Robert, J. (2022). Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. Journal of Infection 85, 24–30, http://doi.org/10.1016/j.jinf.2022.05.017.
Bonnet, I., Haddad, E., Guglielmetti, L., Bémer, P., Bernard, L., Bourgoin, A., Brault, R., Catho, G., Caumes, E., Escaut, L., Fourniols, E., Fréchet-Jachym, M., Gaudart, A., Guillot, H., Lafon-Desmurs, B., Lanoix, J.-P., Lanotte, P., Lemaignen, A., Lemaire, B., Lemaitre, N., Michau, C., Morand, P., Mougari, F., Marigot-Outtandy, D., Patrat-Delon, S., Perpoint, T., Piau, C., Pourcher, V., Zarrouk, V., Zeller, V., Veziris, N., Jauréguiberry, S. and Aubry, A. (2022). Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Microorganisms 10, 1215, http://doi.org/10.3390/microorganisms10061215.
Chaptal, M., Andrejak, C., Bonifay, T., Beillard, E., Guillot, G., Guyomard-Rabenirina, S., Demar, M., Trombert-Paolantoni, S., Jacomo, V., Mosnier, E., Veziris, N., Djossou, F., Epelboin, L. and Group, F. G. P. working (2022). Epidemiology of infection by pulmonary non-tuberculous mycobacteria in French Guiana 2008–2018. PLOS Neglected Tropical Diseases 16, e0010693, http://doi.org/10.1371/journal.pntd.0010693.
Chiron, R., Hoefsloot, W., Van Ingen, J., Marchandin, H., Kremer, L., Morisse-Pradier, H., Charriot, J., Mallet, J.-P., Herrmann, J.-L., Caimmi, D., Moreau, J., Dumont, Y., Godreuil, S., Bergeron, A., Drevait, M., Bouzat-Rossigneux, E., Terrail, N., Andrejak, C., Veziris, N., Grenet, D., Coudrat, A. and Catherinot, E. (2022). Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience. Open Forum Infect Dis 9, ofac465, http://doi.org/10.1093/ofid/ofac465.
Daniau, C., Lecorche, E., Mougari, F., Benmansour, H., Bernet, C., Blanchard, H., Robert, J., Berger-Carbonne, A. and Cambau, E. (2022). Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020. Emerg Infect Dis 28, 518–526, http://doi.org/10.3201/eid2803.211791.
Daniau, C., Berger-Carbonne, A. and Cambau, E. (2022). Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020 (response). Emerg Infect Dis 28, 1303–1304, http://doi.org/10.3201/eid2806.220686.
De Castro, N., Mechaï, F., Bachelet, D., Canestri, A., Joly, V., Vandenhende, M., Boutoille, D., Kerjouan, M., Veziris, N., Molina, J. M., Grall, N., Tattevin, P., Laouénan, C., Yazdanpanah, Y. and for the FAST TB Study Group (2022). Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB). Open Forum Infectious Diseases 9, ofac353, http://doi.org/10.1093/ofid/ofac353.
Eimer, J., Fréchet-Jachym, M., Le Dû, D., Caumes, E., El-Helali, N., Marigot-Outtandy, D., Mechai, F., Peytavin, G., Pourcher, V., Rioux, C., Yazdanpanah, Y., Robert, J., Guglielmetti, L. and for the LZDM group (2022). Increased linezolid plasma concentrations are associated with the development of severe toxicity in MDR-TB treatment. Clinical Infectious Diseases ciac485, http://doi.org/10.1093/cid/ciac485.
Group, A. S. T., Georghiou, S. B., Rodwell, T. C., Korobitsyn, A., Abbadi, S. H., Ajbani, K., Alffenaar, J.-W., Alland, D., Alvarez, N., Andres, S., Ardizzoni, E., Aubry, A., Baldan, R., Ballif, M., Barilar, I., Böttger, E. C., Chakravorty, S., Claxton, P. M., Cirillo, D. M., Comas, I., Coulter, C., Denkinger, C. M., Derendinger, B., Desmond, E. P., Steenwinkel, J. E. M. de, Dheda, K., Diacon, A. H., Dolinger, D. L., Dooley, K. E., Egger, M., Ehsani, S., Farhat, M. R., Fattorini, L., Finci, I., Ray, L. F. L., Furió, V., Groenheit, R., Gumbo, T., Heysell, S. K., Hillemann, D., Hoffmann, H., Hsueh, P.-R., Hu, Y., Huang, H., Hussain, A., Ismail, F., Izumi, K., Jagielski, T., Johnson, J. L., Kambli, P., Kaniga, K., Karunaratne, G. H. R. E., Sharma, M. K., Keller, P. M., Kelly, E. C., Kholina, M., Kohli, M., Kranzer, K., Laurenson, I. F., Limberis, J., Lin, S.-Y. G., Liu, Y., López-Gavín, A., Lyander, A., Machado, D., Martinez, E., Masood, F., Mitarai, S., Mvelase, N. R., Niemann, S., Nikolayevskyy, V., Maurer, F. P., Merker, M., Miotto, P., Omar, S. V., Otto-Knapp, R., Palaci, M., Gutiérrez, J. J. P., Peacock, S. J., Peloquin, C. A., Perera, J., Pierre-Audigier, C., Pholwat, S., Posey, J. E., Prammananan, T., Rigouts, L., Robledo, J., Rockwood, N., Rodrigues, C., Salfinger, M., Schechter, M. C., Seifert, M., Sengstake, S., Shinnick, T., Shubladze, N., Sintchenko, V., Sirgel, F., Somasundaram, S., Sterling, T. R., Spitaleri, A., Streicher, E., Supply, P., Svensson, E., Tagliani, E., Tahseen, S., Takaki, A., Theron, G., Torrea, G., Deun, A. V., Ingen, J. van, Rie, A. V., Soolingen, D. van, Jr, R. V., Venter, A., Veziris, N., Villellas, C., Viveiros, M., Warren, R., Wen, S., Werngren, J., Wilkinson, R. J., Yang, C., Yılmaz, F. F., Zhang, T., Zimenkov, D., Ismail, N., Köser, C. U. and Schön, T. (2022). Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00166-2022.
Guglielmetti, L., Günther, G., Leu, C., Cirillo, D., Duarte, R., Garcia-Basteiro, A. L., Goletti, D., Jankovic, M., Kuksa, L., Maurer, F. P., Méchaï, F., Tiberi, S., Leth, F. van, Veziris, N. and Lange, C. (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00388-2022.
Guyeux, C., Senelle, G., Refrégier, G., Bretelle-Establet, F., Cambau, E. and Sola, C. (2022). Connection between two historical tuberculosis outbreak sites in Japan, Honshu, by a new ancestral Mycobacterium tuberculosis L2 sublineage. Epidemiology & Infection 150, http://doi.org/10.1017/S0950268822000048.
Holmgaard, F. B., Guglielmetti, L., Lillebaek, T., Andersen, Å. B., Wejse, C. and Dahl, V. N. (2022). Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Clin Infect Dis ciac876, http://doi.org/10.1093/cid/ciac876.
Khan, U. and Guglielmetti, L. (2022). Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB. The International Journal of Tuberculosis and Lung Disease 26, 900–901, http://doi.org/10.5588/ijtld.22.0328.
Kherabi, Y., Fréchet-Jachym, M., Rioux, C., Yazdanpanah, Y., Méchaï, F., Pourcher, V., Robert, J. and Guglielmetti, L. (2022). Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019. Emerg Infect Dis 28, 1796–1804, http://doi.org/10.3201/eid2809.220458.
Kherabi, Y., Tunesi, S., Kay, A. and Guglielmetti, L. (2022). Preventive Therapy for Contacts of Drug-Resistant Tuberculosis. Pathogens 11, 1189, http://doi.org/10.3390/pathogens11101189.
Kilinç, G., Walburg, K. V., Franken, K. L. M. C., Valkenburg, M. L., Aubry, A., Haks, M. C., Saris, A. and Ottenhoff, T. H. M. (2022). Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium. Front Cell Infect Microbiol 12, 872361, http://doi.org/10.3389/fcimb.2022.872361.
Kraef, C., Lindquist, E., Svensson, E. and Cambau, E. (2022). Diagnostic toolkit for tuberculosis: should we include urine lipoarabinomannan (LAM) detection in the WHO European Region? Clinical Microbiology and Infection, http://doi.org/10.1016/j.cmi.2022.06.022.
Lange, C., Böttger, E. C., Cambau, E., Griffith, D. E., Guglielmetti, L., van Ingen, J., Knight, S. L., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., Wagner, D., Winthrop, K., Daley, C. L., Lange, C., Andrejak, C., Böttger, E., Cambau, E., Griffith, D., Guglielmetti, L., van Ingen, J., Knight, S., Leitman, P., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., Wagner, D., Wallace, R. J., Winthrop, K. and Daley, C. (2022). Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. The Lancet Infectious Diseases, http://doi.org/10.1016/S1473-3099(21)00586-7.
Le Ray, L. F., Aubry, A., Sougakoff, W., Revest, M., Robert, J., Bonnet, I., Veziris, N. and Morel, F. (2022). atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure. Emerg Infect Dis 28, 1062–1064, http://doi.org/10.3201/eid2805.212517.
Maitre, T., Morel, F., Brossier, F., Sougakoff, W., Jaffre, J., Cheng, S., Veziris, N., Aubry, A. and on behalf of the NRC-MyRMA (2022). How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance. Microorganisms 10, 1436, http://doi.org/10.3390/microorganisms10071436.
Marijke Braet, S., Jouet, A., Aubry, A., Van Dyck-Lippens, M., Lenoir, E., Assoumani, Y., Baco, A., Mzembaba, A., Cambau, E., Vasconcellos, S. E. G., Rigouts, L., Suffys, P. N., Hasker, E., Supply, P. and de Jong, B. C. (2022). Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. The Lancet Microbe 3, e693–e700, http://doi.org/10.1016/S2666-5247(22)00117-3.
Migliori, G. B., Wu, S. J., Matteelli, A., Zenner, D., Goletti, D., Ahmedov, S., Al-Abri, S., Allen, D. M., Balcells, M. E., Garcia-Basteiro, A. L., Cambau, E., Chaisson, R. E., Chee, C. B. E., Dalcolmo, M. P., Denholm, J. T., Erkens, C., Esposito, S., Farnia, P., Friedland, J. S., Graham, S., Hamada, Y., Harries, A. D., Kay, A. W., Kritski, A., Manga, S., Marais, B. J., Menzies, D., Ng, D., Petrone, L., Rendon, A., Silva, D. R., Schaaf, H. S., Skrahina, A., Sotgiu, G., Thwaites, G., Tiberi, S., Tukvadze, N., Zellweger, J.-P., D’Ambrosio, L., Centis, R. and Ong, C. W. M. (2022). Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis 26, 190–205, http://doi.org/10.5588/ijtld.21.0753.
Tunesi, S., Dû, D. L., Gualano, G., Millet, J.-P., Skrahin, A., Bothamley, G., Casas, X., Goletti, D., Lange, C., Musso, M., Palmieri, F., Pourcher, V., Rioux, C., Skrahina, A., Veziris, N., Viatushka, D., Jachym-Fréchet, M. and Guglielmetti, L. (2022). Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. Journal of Infection, http://doi.org/10.1016/j.jinf.2022.03.004.
Vongthilath-Moeung, R., Plojoux, J., Poncet, A., Renzi, G., Veziris, N., Schrenzel, J. and Janssens, J.-P. (2022). Nontuberculous Mycobacteria under Scrutiny in the Geneva Area (2015–2020). RES 101, 367–375, http://doi.org/10.1159/000520033.
Wetzstein, N., Drummer, A.-P., Bockey, A., Herrmann, E., Küpper-Tetzel, C. P., Graf, C., Koch, B., Goetsch, U., Vehreschild, M. J. G. T., Guglielmetti, L., Lange, B., Wichelhaus, T. A. and Stephan, C. (2022). Occurrence of extrapulmonary tuberculosis is associated with geographical origin: spatial characteristics of the Frankfurt TB cohort 2013–2018. Infection, http://doi.org/10.1007/s15010-022-01921-9.